Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - Taylor & Francis
Objective This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …
相关文章

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - dovepress.com
Objective: This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.

WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - europepmc.org
Objective This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …
[HTML] nih.gov

[HTML][HTML] Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Objective This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …
[PDF] semanticscholar.org

[PDF][PDF] Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - pdfs.semanticscholar.org
Objective: This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

WX Hu, JC Peng, Y Wang, H Jin… - International journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …